Loading...


*  Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma - Full Text View - ClinicalTrials.gov
It is not yet known which combination chemotherapy regimen is more effective for treating anaplastic large cell lymphoma. ... stage I childhood anaplastic large cell lymphoma. stage II childhood anaplastic large cell lymphoma. stage III childhood ... anaplastic large cell lymphoma. stage IV childhood anaplastic large cell lymphoma. recurrent childhood anaplastic large cell ... Genetic and Rare Diseases Information Center resources: Lymphosarcoma Lymphoma, Large-cell Anaplastic Large Cell Lymphoma ...
  https://clinicaltrials.gov/ct2/show/NCT00006455
*  Brentuximab vedotin | Leukemia and Lymphoma Society
Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ... Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30- expressing mycosis fungoides (MF) who have received prior ... The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission ... Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after ...
  https://www.lls.org/treatment/types-of-treatment/chemotherapy-and-other-drug-therapies/drug-listings/brentuximab-vedotin
*  Search of: 'Lymphoma large-cell' - List Results - ClinicalTrials.gov
Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma ... s Lymphoma or Anaplastic Large Cell Lymphoma'. *Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell ... A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib. *Systemic Anaplastic Large-Cell Lymphoma ... and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma. *Anaplastic Large Cell Lymphoma ...
  https://clinicaltrials.gov/ct2/results?cond=%22Lymphoma+large-cell%22
*  Phase 2 Trial Update of Adcetris in Cutaneous T-Cell Lymphoma - MPR
... in patients with cutaneous T-cell lymphoma (CTCL). ... primary cutaneous anaplastic large cell lymphoma or mycosis ... the treatment of systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen. ... in patients with cutaneous T-cell lymphoma (CTCL). At the time of data analysis, 17 of 23 enrolled patients had received at ... or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. Adcetris is ...
  http://www.empr.com/drugs-in-the-pipeline/phase-2-trial-update-of-adcetris-in-cutaneous-t-cell-lymphoma/article/225021/
*  Adcetris - FDA prescribing information, side effects and uses
... in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30- ... after failure of at least one prior multi-agent chemotherapy regimen.. Relapsed pcALCL or CD30-expressing MF. ​Adcetris is ... Table 7: Adverse Reactions Reported in ≥10% of Patients with Relapsed Systemic Anaplastic Large Cell Lymphoma (Study 2). sALCL ... Relapsed Systemic Anaplastic Large Cell Lymphoma. 1.8 mg/kg up to a maximum of 180 mg. Intravenous infusion over 30 minutes. ...
  https://www.drugs.com/pro/adcetris.html
*  Adcetris (Brentuximab Vedotin): Side Effects, Interactions, Warning, Dosage & Uses
Large Cell Lymphoma And CD30-expressingMycosis Fungoides. Randomized Clinical Trial In Primary Cutaneous Anaplastic Large Cell ... after failure of at least one prior multi-agent chemotherapy regimen.. Relapsed pcALCL Or CD30-Expressing MF. ADCETRIS is ... Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides. 1.8 mg/kg up to a maximum of ... Table 6: Adverse Reactions Reported in ≥10% of Patients with Relapsed Systemic Anaplastic Large Cell Lymphoma (Study 2). ...
  https://www.rxlist.com/adcetris-drug.htm
*  CD30 - Wikipedia
... are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens Systemic anaplastic large cell lymphoma ( ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ... Lee SY, Park CG, Choi Y (Feb 1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic ... "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ...
  https://en.wikipedia.org/wiki/CD30
*  Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at International Conferenc - AOL Finance
Clinical Data at International Conference on Malignant Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NAS: ... of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-cell Lymphoma ( ... or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the ... and systemic anaplastic large cell lymphoma (sALCL), that was granted accelerated approval by the FDA in August 2011 for ...
  https://www.aol.com/article/finance/2013/06/21/seattle-genetics-highlights-adcetris-brentuximab-v/20630703/
*  FDA Tags Seattle Genetics's Lymphoma Drug With Breakthrough Tag | BioSpace
FDA Tags Seattle Genetics's Lymphoma Drug With Breakthrough Tag - read this article along with other careers information, tips ... classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also ... cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is ...
  https://www.biospace.com/article/releases/fda-tags-seattle-genetics-s-lymphoma-drug-with-breakthrough-tag-/
*  Seattle Genetics' ASH 2012 Presentations Highlight ADCETRIS® And Demonstrate Leadership In The Development Of Antibody-Drug...
... and systemic anaplastic large cell lymphoma (sALCL), as well as in some types of cutaneous T-cell lymphoma (CTCL), B-cell ... or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the ... treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent ... ADCETRIS is currently not approved for use in CTCL, B-cell lymphomas, and front-line treatment of HL or MTCL. ...
  https://www.thestreet.com/story/11757286/1/seattle-genetics8217-ash-2012-presentations-highlight-adcetris174-and-demonstrate-leadership-in-the-development-of-antibody-drug-conjugates-adcs.html
*  Why Investors Should Pay Attention to Seattle Genetics' Drug Trial | BioSpace
... and accelerated approval in patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior ... multi-agent chemotherapy regimen. It also received conditional marketing authorization in 2012 by the European Commission for ... for the treatment of classical Hodgkin lymphoma after failure of autologous hematopoietic stem cell transplantation, for the ... She writes, "If successful with previously untreated Hodgkin lymphoma, the trial could lead to expanded use of Adcetris and ...
  https://www.biospace.com/article/why-investors-should-pay-attention-to-seattle-genetics-drug-trial-/
*  Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and...
... for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) ... chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large ... by Health Canada in February 2013 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from ...
  http://www.tmcnet.com/news/2013/02/01/6896249.htm
*  Takeda Showcases Broadened Oncology Portfolio Through Data Presentations at Upcoming Medical Meetings | Business Wire
International Conference on Malignant Lymphoma 2017 (ICML), June 14-17 in Lugano, Switzerland. Presentations at this year's ... cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved ... approval for the treatment of patients with systemic anaplastic large ... frontline mature T-cell lymphomas, as well as the completed ALCANZA trial in cutaneous T-cell lymphoma for which a supplemental ...
  https://www.ntbinfo.no/pressemelding/takeda-showcases-broadened-oncology-portfolio-through-data-presentations-at-upcoming-medical-meetings?publisherId=90063&releaseId=15248612
*  Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive...
... antibody titer in children with ALK-positive anaplastic large cell lymphoma (ALCL) was reported... ... analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002; ... Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a ... and anti-anaplastic lymphoma kinase (ALK) antibody titer in children with ALK-positive anaplastic large cell lymphoma (ALCL) ...
  https://rd.springer.com/article/10.1007/s12185-017-2338-6
*  European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior...
... for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy- Providing an Innovative Treatment Option to ... and primary cutaneous anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level evidence. In two single ... PML has been reported in patients who received ADCETRIS after receiving multiple prior chemotherapy regimens. PML is a rare ... accelerated approval for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at ...
  https://www.takeda.com/newsroom/newsreleases/2018/european-commission-approves-adcetris-brentuximab-vedotin-for-cd30-positive-cutaneous-t-cell-lymphoma-after-one-prior-systemic-therapy-providing-an-innovative-treatment-option-to-patients/
*  Resources for For Clinicians - ADC Review ADC Review
Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. ... Food and Drug Administration for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL ... Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after ... failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. ...
  https://adcreview.com/resources-for-for-clinicians/
*  ADCETRIS, US | epgonline.org
Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cel ... Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen (1.3). ... 1.3 Systemic Anaplastic Large Cell Lymphoma (sALCL) ADCETRIS is indicated for treatment of patients with sALCL after failure of ... and systemic anaplastic large cell lymphoma (sALCL), including 160 patients in two uncontrolled single-arm trials (Studies 1 ...
  https://www.epgonline.org/global/drugs/adcetris/
*  Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression - Cancer Therapy Advisor
Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted ... and for systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen. ... for the treatment of Hodgkin lymphoma after failure of ASCT or after at least two prior multi-agent chemotherapy regimens in ... FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma. *Ivermectin Induces Apoptosis Through ...
  http://www.cancertherapyadvisor.com/ash-2014/brentuximab-vedotin-hodgkin-lymphoma-survival-stem-cell/article/387700/
*  Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(TM) (Brentuximab Vedotin) in Pediatric Patients at EMCC...
... or systemic anaplastic large cell lymphoma (sALCL) (n=4) and had failed at least one prior chemotherapy regimen. The data were ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from ... The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also ... About Hodgkin Lymphoma and Systemic ALCL. Lymphoma is a general term for a group of cancers that originate in the lymphatic ...
  http://www.checkorphan.org/news/millennium-and-seattle-genetics-present-clinical-data-on-adcetris-tm-brentuximab-vedotin-in-pediatric-patients-at-emcc-annual-meeting
*  FLASCO / FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell...
... sALCL after failure of at least one prior multi-agent chemotherapy regimen, and (5) primary cutaneous anaplastic large cell ... for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), ... patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas ... Secondary endpoints include PFS in patients with systemic anaplastic large cell lymphoma (sALCL), complete remission rate, ...
  https://www.flasco.org/fda-grants-breakthrough-therapy-designation-to-adcetris-brentuximab-vedotin-for-frontline-peripheral-t-cell-lymphomas/
*  Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH...
... large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS ... ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma ( ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from ... stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ...
  https://www.businesswire.com/news/home/20121210006357/en/Seattle-Genetics-Reports-Data-Phase-Trial-ADCETRIS%C2%AE
*  Formulary decision highlights march 2016
for systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. ... For the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi- agent ... hematopoietic stem cell transplantation (HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in ... least two prior multi agent chemotherapy regimens in patients who are not autologous stem cell transplant candidates OR 2. ...
  http://gotomydoctor.com/p/provider.ghc.org1.html
*  Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T...
... classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also ... cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved ... cutaneous anaplastic large cell lymphoma who require systemic therapy and have received one prior systemic therapy. These ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Cutaneous lymphomas are a category of ...
  https://www.enhancedonlinenews.com/news/eon/20170620005552/en
*  Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline...
... cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved ... approval for the treatment of patients with systemic anaplastic large ... There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is ... ongoing ECHELON-2 trial in frontline mature T-cell lymphomas, the completed ALCANZA trial in cutaneous T-cell lymphoma that ...
  http://investor.seagen.com/news-releases/news-release-details/seattle-genetics-submits-supplemental-biologics-license-0?ID=2313803&c=124860&p=irol-newsArticle_pf
*  Africa Live News
... sALCL after failure of at least one prior multi-agent chemotherapy regimen, and (5) primary cutaneous anaplastic large cell ... and primary cutaneous anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level evidence. In two single ... Patient Characteristics and Treatment Patterns in the First-Line and Second-Line Treatment of Diffuse Large B-Cell Lymphoma and ... Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup ...
  http://africa-live.at.ua/news/takeda_to_present_data_during_60th_american_society_of_hematology_annual_meeting_on_wide_array_of_treatment_needs_for_blood_cancers/2018-11-08-11910